Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

The ongoing COVID-19 pandemic has resulted in over 25.0 million confirmed cases and
over 840,000 deaths globally. As the third severe respiratory disease outbreak caused by …

Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of
immune escape, challenging the present COVID-19 prophylaxis and clinical interventions …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

The SARS-CoV-2 pandemic has led to an urgent need to understand the molecular basis for
immune recognition of SARS-CoV-2 spike (S) glycoprotein antigenic sites. To define the …